About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Myc
myelocytomatosis oncogene
MGI:97250
199 phenotypes from 42 alleles in 39 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Gt(ROSA)26Sortm1(Myc)Rcse/Gt(ROSA)26Sortm1(Myc)Rcse
Tg(Wap-cre)11738Mam/0
involves: 129 * C57BL/6 * SJL 		abnormal branching of the mammary ductal tree J:169403
abnormal chromosome number J:169403
abnormal mammary gland epithelium physiology J:169403
chromosomal instability J:169403
increased mammary gland apoptosis J:169403
normal neoplasm J:169403
Gt(ROSA)26Sortm2(myc*T58A)Rcse/Gt(ROSA)26Sortm2(myc*T58A)Rcse
Tg(Wap-cre)11738Mam/0
involves: 129 * C57BL/6 * SJL 		abnormal branching of the mammary ductal tree J:169403
abnormal involution of the mammary gland J:169403
abnormal mammary gland alveolus morphology J:169403
abnormal mammary gland epithelium physiology J:169403
aneuploidy J:169403
chromosomal instability J:169403
decreased tumor-free survival time J:169403
increased brain tumor incidence J:169403
increased mammary adenocarcinoma incidence J:169403
increased pituitary gland tumor incidence J:169403
mammary gland alveolar hyperplasia J:169403
mammary gland hyperplasia J:169403
polyploidy J:169403
Gt(ROSA)26Sortm3(myc*S62A)Rcse/Gt(ROSA)26Sortm3(myc*S62A)Rcse
Tg(Wap-cre)11738Mam/0
involves: 129 * C57BL/6 * SJL 		abnormal branching of the mammary ductal tree J:169403
abnormal mammary gland alveolus morphology J:169403
aneuploidy J:169403
chromosomal instability J:169403
increased brain tumor incidence J:169403
polyploidy J:169403
Hnf4atm1(cre)Sdv/Hnf4a+
Myctm2.1Atp/Myctm2.1Atp
involves: 129P2/OlaHsd * 129S/SvEv 		normal liver/biliary system phenotype J:137630
normal mortality/aging J:137630
Mycem1(IMPC)Kmpc/Myc+
C57BL/6NTac-Mycem1(IMPC)Kmpc/Kmpc 		abnormal bone structure J:211773
decreased body length J:211773
decreased bone mineral content J:211773
decreased bone mineral density J:211773
decreased fluid intake J:211773
decreased prepulse inhibition J:211773
increased startle reflex J:211773
increased total body fat amount J:211773
short tibia J:211773
Mycem1(IMPC)Kmpc/Mycem1(IMPC)Kmpc
C57BL/6NTac-Mycem1(IMPC)Kmpc/Kmpc 		preweaning lethality, complete penetrance J:211773
Myctm1(Nmyc1)Fwa/Myctm1(Nmyc1)Fwa
involves: 129P2/OlaHsd * C57BL/6 		prenatal lethality, complete penetrance J:62573
Myctm1.1(MYC)Gwbk/Myctm1.1(MYC)Gwbk
involves: BALB/cJ * C57BL/6 		no abnormal phenotype detected J:189677
Myctm1.1(Nmyc1)Fwa/Myctm1.1(Nmyc1)Fwa
involves: 129P2/OlaHsd * C57BL/6 		abnormal skeletal muscle morphology J:62573
cyanosis J:62573
decreased birth body size J:62573
decreased birth weight J:62573
decreased body size J:62573
decreased body weight J:62573
normal immune system phenotype J:62573
neonatal lethality, incomplete penetrance J:62573
Myctm1.1Cksn/Myctm1.1Cksn
B6.129-Myctm1.1Cksn 		normal immune system phenotype J:170508
Myctm1.1Dlev/Myctm1.1Dlev
involves: 129S4/SvJae * C57BL/6NCrl 		no abnormal phenotype detected J:186832
Myctm1.1Dmlo/Myctm1.1Dmlo
involves: 129S2/SvPas * BALB/c * C57BL/6J * MF1 		no abnormal phenotype detected J:70610
Myctm1.1Itl/Myctm1.1Itl
involves: 129S6/SvEvTac * C57BL/6NTac 		abnormal enterocyte physiology J:188927
abnormal enterocyte proliferation J:188927
abnormal intestinal enteroendocrine cell morphology J:188927
abnormal intestinal goblet cell morphology J:188927
abnormal intestine morphology J:188927
abnormal large intestine crypts of Lieberkuhn morphology J:188927
abnormal response to injury J:188927
abnormal small intestine crypts of Lieberkuhn morphology J:188927
decreased Paneth cell number J:188927
decreased small intestinal villus size J:188927
Myctm1Atp/Myc+
B6.129P2-Myctm1Atp 		abnormal NK cell physiology J:132730
decreased memory T cell number J:132730
decreased T cell proliferation J:132730
normal immune system phenotype J:132730
Myctm1Atp/Myc+
involves: 129P2/OlaHsd * FVB/N 		decreased body size J:73369
decreased body weight J:73369
decreased bone marrow cell number J:73369
decreased fetal size J:73369
decreased fibroblast proliferation J:73369
decreased T cell proliferation J:73369
decreased white adipose tissue amount J:73369
lymph node hypoplasia J:73369
lymphoid hypoplasia J:73369
postnatal growth retardation J:73369
short tail J:73369
small lymphoid organs J:73369
spleen hypoplasia J:73369
Myctm1Atp/Myctm1Atp
involves: 129P2/OlaHsd 		abnormal chorion morphology J:137630
abnormal placenta morphology J:137630
abnormal trophoblast layer morphology J:137630
normal cardiovascular system phenotype J:137630
placental labyrinth hypoplasia J:137630
Myctm1Atp/Myctm1Atp
involves: 129P2/OlaHsd * FVB/N 		absent common myeloid progenitor cells J:73369
absent erythroid progenitor cell J:73369
absent fibroblast proliferation J:73369
decreased embryo size J:73369
embryonic lethality during organogenesis, complete penetrance J:73369
pale yolk sac J:73369
Myctm1Atp/Myctm2.1Atp
involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL 		decreased body weight J:73369
decreased bone marrow cell number J:73369
decreased T cell proliferation J:73369
normal immune system phenotype J:73369
lymph node hypoplasia J:73369
spleen hypoplasia J:73369
Myctm1Atp/Myctm2.1Atp
Tg(Mx1-cre)1Cgn/0
involves: 129P2/OlaHsd * C57BL/6 * CBA * FVB/N * SJL 		normal immune system phenotype J:73369
Myctm1Brd/Myc+
involves: 129S7/SvEvBrd * C57BL/6J 		decreased litter size J:4556
reduced female fertility J:4556
Myctm1Brd/Myctm1Brd
involves: 129S7/SvEvBrd * C57BL/6J 		abnormal embryo turning J:4556
distended pericardium J:4556
embryonic growth retardation J:4556
embryonic lethality during organogenesis, complete penetrance J:4556
enlarged heart J:4556
open neural tube J:4556
Myctm1Jlc/Myctm1Jlc
involves: 129S7/SvEvBrd 		abnormal angiogenesis J:79427
abnormal dorsal aorta morphology J:79427
abnormal embryonic erythropoiesis J:79427
abnormal vascular development J:79427
abnormal vasculogenesis J:79427
abnormal visceral yolk sac morphology J:79427
decreased cell proliferation J:79427
decreased common myeloid progenitor cell number J:79427
decreased embryo size J:79427
decreased erythroid progenitor cell number J:79427
decreased tumor incidence J:79427
Myctm1Lbox/Myc+
involves: 129S1/Sv * 129X1/SvJ * FVB/N 		enlarged lymph nodes J:97900
enlarged spleen J:97900
increased B cell derived lymphoma incidence J:97900
increased B cell number J:97900
increased spleen weight J:97900
premature death J:97900
Myctm1Lbox/Myctm1Lbox
involves: 129S1/Sv * 129X1/SvJ * FVB/N 		decreased T cell number J:97900
enlarged lymph nodes J:97900
enlarged spleen J:97900
increased B cell apoptosis J:97900
increased B cell derived lymphoma incidence J:97900
increased B cell number J:97900
increased B cell proliferation J:97900
increased spleen weight J:97900
premature death J:97900
Myctm1Slek/Myctm1Slek
involves: 129 		no abnormal phenotype detected J:131281
Myctm2.1Atp/Myc+
involves: 129P2/OlaHsd * C57BL/6 * SJL 		decreased body weight J:73369
decreased T cell proliferation J:73369
Myctm2.1Atp/Myctm2.1Atp
Edil3Tg(Sox2-cre)1Amc/Edil3+
involves: 129P2/OlaHsd * C57BL/6 * CBA 		abnormal common myeloid progenitor cell morphology J:137630
abnormal proerythroblast morphology J:137630
normal cardiovascular system phenotype J:137630
decreased embryo size J:137630
decreased erythroid progenitor cell number J:137630
embryonic lethality during organogenesis, complete penetrance J:137630
impaired hematopoiesis J:137630
liver hypoplasia J:137630
pale yolk sac J:137630
Myctm2.1Atp/Myctm2.1Atp
Tg(Mx1-cre)1Cgn/0
involves: 129P2/OlaHsd * C57BL/6 * CBA * FVB/N * SJL 		absent fibroblast proliferation J:73369
normal immune system phenotype J:73369
Myctm2.1Atp/Myctm2.1Atp
Tg(Pdx1-cre)1Herr/0
involves: 129P2/OlaHsd * C57BL/6J * CBA/J 		abnormal enzyme/coenzyme activity J:146087
abnormal pancreas development J:146087
abnormal pancreas morphology J:146087
abnormal pancreas size J:146087
abnormal pancreatic acinar cell morphology J:146087
abnormal pancreatic acinus morphology J:146087
abnormal pancreatic duct morphology J:146087
absent pancreatic acinar cells J:146087
decreased pancreas weight J:146087
normal endocrine/exocrine gland phenotype J:146087
pancreas hypoplasia J:146087
Myctm2.1Atp/Myctm2.1Atp
Tg(Tek-cre)1Rwng/0
involves: 129P2/OlaHsd * FVB/N 		abnormal hematopoietic system morphology/development J:137630
abnormal liver morphology J:137630
normal cardiovascular system phenotype J:137630
embryonic lethality during organogenesis, complete penetrance J:137630
liver hypoplasia J:137630
pale yolk sac J:137630
small liver J:137630
Myctm2Dmlo/Myctm2Dmlo
involves: 129S2/SvPas * BALB/c * C57BL/6J * MF1 		no abnormal phenotype detected J:70610
Myctm2Fwa/Myc+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S6/SvEvTac * C57BL/6 * CBA 		belly spot J:121871
Myctm2Fwa/Myctm2Fwa
involves: 129S6/SvEvTac 		no abnormal phenotype detected J:67222
Myctm2Fwa/Myctm2Fwa
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac 		decreased B cell proliferation J:67222
Myctm2Fwa/Myctm2Fwa
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S6/SvEvTac * C57BL/6 * CBA 		abnormal auditory brainstem response J:121871
abnormal frontal bone morphology J:121871
abnormal malleus morphology J:121871
abnormal middle ear ossicle morphology J:121871
abnormal parietal bone morphology J:121871
absent pinna reflex J:121871
conductive hearing impairment J:121871
decreased body size J:121871
decreased body weight J:121871
short malleus manubrium J:121871
short nasal bone J:121871
short snout J:121871
small cranium J:121871
small malleus J:121871
small nasal bone J:121871
variable body spotting J:121871
Myctm3(Tcrb)Fwa/Myc+
involves: 129 		abnormal T cell receptor beta chain V(D)J recombination J:131995
Myctm4.1Fwa/Myctm4.1Fwa
involves: 129S6/SvEvTac 		induced chromosome breakage J:150339
Myctm37Mnz/Myc+
involves: C57BL/6 		induced chromosome breakage J:145691
Myctm39Mnz/Myc+
involves: C57BL/6 		spontaneous chromosome breakage J:145691
Tg(Alb1-Myc)#Sst/0
involves: C57BL/6 * CBA 		abnormal hepatocyte morphology J:34434
increased hepatocellular carcinoma incidence J:34434
increased liver adenoma incidence J:34434
increased liver weight J:34434
Tg(Ela1-Myc)158Bri/0
involves: C57BL/6 * SJL 		exocrine pancreas atrophy J:76992
increased metastatic potential J:76992
increased pancreas tumor incidence J:76992
increased pancreatic acinar cell carcinoma incidence J:76992
jaundice J:76992
premature death J:76992
small pancreas J:76992
Tg(Ela1-Myc)159Bri/0
involves: C57BL/6 * SJL 		exocrine pancreas atrophy J:76992
increased metastatic potential J:76992
increased pancreas tumor incidence J:76992
increased pancreatic acinar cell carcinoma incidence J:76992
jaundice J:76992
premature death J:76992
small pancreas J:76992
Tg(Ela1-Myc)160Bri/0
involves: C57BL/6 * SJL 		exocrine pancreas atrophy J:76992
increased metastatic potential J:76992
increased pancreas tumor incidence J:76992
increased pancreatic acinar cell carcinoma incidence J:76992
jaundice J:76992
premature death J:76992
small pancreas J:76992
Tg(HBB-Myc)#Cos/0
involves: C57BL/6J * CBA/J 		abnormal immune system organ morphology J:276641
anemia J:276641
normal cardiovascular system phenotype J:276641
decreased body size J:276641
decreased hematocrit J:276641
enlarged kidney J:276641
glomerulosclerosis J:276641
hyperventilation J:276641
increased adenoma incidence J:276641
increased blood urea nitrogen level J:276641
increased circulating creatinine level J:276641
kidney failure J:276641
kidney inflammation J:276641
lethargy J:276641
muscular atrophy J:276641
polycystic kidney J:276641
premature death J:276641
renal interstitial fibrosis J:276641
Tg(HBVX*,-Myc)#Skp/0
Not Specified 		increased hepatocellular carcinoma incidence J:81098
Tg(HBVX*,-Myc)#Skp/Tg(HBVX*,-Myc)#Skp
Not Specified 		abnormal cell nucleus morphology J:202732
abnormal definitive hematopoiesis J:81098
abnormal hepatocyte mitochondrial morphology J:202732
abnormal hepatocyte morphology J:81098
abnormal liver lobule morphology J:81098
abnormal liver morphology J:81098
abnormal liver sinusoid morphology J:81098
decreased liver glycogen level J:81098
enlarged liver J:81098
focal hepatic necrosis J:81098
increased hepatocellular carcinoma incidence J:81098
increased liver iron level J:81098
increased liver weight J:81098
increased macrophage cell number J:81098
liver vascular congestion J:81098
microvesicular hepatic steatosis J:81098
Tg(IghMyc)22Bri/0
B6.Cg-Tg(IghMyc)22Bri/J 		enlarged lymph nodes J:164200
increased lymphoma incidence J:164200
premature death J:164200
spleen hyperplasia J:164200
Tg(IghMyc)22Bri/?
involves: C57BL * C57BL/6 * SJL 		enlarged spleen J:121564
increased lymphocyte cell number J:121564
increased lymphoma incidence J:121564
increased metastatic potential J:121564
premature death J:121564
Tg(IghMyc)22Bri/0
involves: C57BL * C57BL/6 * SJL 		increased lymphoma incidence J:117023
premature death J:117023
Tg(IghMyc)22Bri/0
involves: C57BL/6 * SJL 		abnormal lymphopoiesis J:78177
enlarged lymph nodes J:78177
enlarged spleen J:78177
enlarged thymus J:78177
increased B cell derived lymphoma incidence J:78177, J:186117
increased leukemia incidence J:78177
increased leukocyte cell number J:186117
increased lymphoma incidence J:78177, J:223213
increased pre-B cell number J:223213
increased sarcoma incidence J:78177
increased tumor incidence J:78177
premature death J:78177, J:186117, J:223213
Tg(IghMyc)22Bri/0
involves: C57BL/6N * SJL 		increased B cell apoptosis J:214383
increased lymphoma incidence J:214383
premature death J:214383
Tg(IghMyc)186Brn/0
involves: C57BL/LiA * CBA/BrA 		abnormal cell cycle J:142390
abnormal intracellular organelle morphology J:142390
abnormal mitosis J:142390
binucleate J:142390
Tg(MMTV-Myc)141-3Led/0
involves: C57BL/6J * CD-1 		increased B cell derived lymphoma incidence J:62465
increased Leydig cell number J:62465
increased tumor incidence J:62465
Tg(MMTV-Myc)WT13Jrn/0
involves: FVB/N 		abnormal mammary gland development J:193362
increased mammary adenocarcinoma incidence J:153233
increased mammary gland tumor incidence J:153233, J:193362
increased metastatic potential J:153233
Tg(MMTV-Myc)WT21Jrn/0
involves: FVB/N 		increased mammary adenocarcinoma incidence J:153233
increased mammary gland tumor incidence J:153233, J:193362
increased metastatic potential J:153233
Tg(MMTV-Myc*T58A)TA14Jrn/0
involves: FVB/N 		abnormal mammary gland development J:193362
increased mammary adenocarcinoma incidence J:153233
increased mammary gland tumor incidence J:153233, J:193362
Tg(MMTV-Myc*T58A)TA39Jrn/0
involves: FVB 		increased mammary gland tumor incidence J:193362
Tg(MMTV-Myc*T58A)TA41Jrn/0
involves: FVB/N 		increased mammary adenocarcinoma incidence J:153233
increased mammary gland tumor incidence J:153233, J:193362
Tg(Pklr-Myc)73Ak/0
B6.Cg-Tg(Pklr-Myc)73Ak 		decreased NK T cell number J:184496
increased hepatocellular carcinoma incidence J:184496
Tg(Pklr-Myc)73Ak/0
involves: C57BL/6 * DBA 		increased hepatocellular carcinoma incidence J:185488
increased hepatoma incidence J:185488
pancreatic islet hyperplasia J:185488
Tg(Thy1-cmyc)1Kio/0
Not Specified 		postnatal lethality, complete penetrance J:129440
Tg(Thy1-cmyc)6Kio/0
Not Specified 		increased T cell derived lymphoma incidence J:129440
respiratory distress J:129440
Tg(Thy1-cmyc)6LKio/0
Not Specified 		increased T cell derived lymphoma incidence J:129440
Tg(WapMyc)212Bri/0
FVB.Cg-Tg(WapMyc)212Bri 		abnormal mammary gland lobule morphology J:114568
abnormal mammary gland morphology J:114568
increased mammary gland tumor incidence J:114568
mammary gland duct hyperplasia J:114568
mammary gland hyperplasia J:114568
Tg(WapMyc)212Bri/0
involves: C57BL/6 * SJL 		increased mammary adenocarcinoma incidence J:56318
increased mammary gland tumor incidence J:56318
lactation failure J:56318
mammary gland alveolar hyperplasia J:56318
premature death J:56318
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory